Acute Myocardial Infarction (AMI)NCT05696379
Angiography Derived Index of Microcirculatory Resistance in Patients With Acute Myocardial Infarction
An observational study of Acute Myocardial Infarction (AMI), run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
Trial summary
Coronary microcirculatory dysfunction has been known to be prevalent even after successful revascularization of acute myocardial infarction (AMI) patients, and has been shown to be associated with poor prognosis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myocardial Infarction (AMI)
- What is being tested?
- Angiography derived index of micro-circulatory resistance (Angio-IMR)
- How many people
- 5,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2017to 31 May 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients admitted with a diagnosis of acute myocardial infarction underwent successful percutaneous coronary intervention.
Who may be able to join
- Acute myocardial infarction patients who underwent successful percutaneous coronary intervention
Who cannot join
- No appropriate coronary angiography images (inferior image quality, image loss, severe arteries overlap, or significant artifact)
- Previous coronary artery bypass graft
Trial locations and contacts
1 site in 1 country.
China1 site
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310009
About this study
Coronary microcirculatory dysfunction has been known to be prevalent even after successful revascularization of acute myocardial infarction (AMI) patients, and has been shown to be associated with poor prognosis. Angiography derived index of micro-circulatory resistance (Angio-IMR) is a novel pressure-wire free approach to assess coronary microvascular disease with great diagnostic performance. The current study will further investigate the prognostic value of Angio-IMR in patients with AMI in multicenter retrospective cohort.
- Conditions
- Acute Myocardial Infarction (AMI)
- Being tested
- Angiography derived index of micro-circulatory resistance (Angio-IMR)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Angiography derived index of micro-circulatory resistance (Angio-IMR)Other
Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.
| Study group | Role | What they receive |
|---|---|---|
| STEMI with high Angio-IMR | Patients with ST segment elevation myocardial infarction and high Angio-IMR Receives: Other: Angiography derived index of micro-circulatory resistance (Angio-IMR) | |
| STEMI with low Angio-IMR | Patients with ST segment elevation myocardial infarction and low Angio-IMR Receives: Other: Angiography derived index of micro-circulatory resistance (Angio-IMR) | |
| NSTEMI with high Angio-IMR | Patients with non-ST segment elevation myocardial infarction and high Angio-IMR Receives: Other: Angiography derived index of micro-circulatory resistance (Angio-IMR) | |
| NSTEMI with low Angio-IMR | Patients with non-ST segment elevation myocardial infarction and low Angio-IMR Receives: Other: Angiography derived index of micro-circulatory resistance (Angio-IMR) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cardiac death or readmission for heart failure in 1 month
Incidence of cardiac death or readmission for heart failure during first 1 month follow-up.
Measured: 1 month
Cardiac death or readmission for heart failure in 6 months
Incidence of cardiac death or readmission for heart failure during first 6 months follow-up.
Measured: 6 month
Cardiac death or readmission for heart failure in 1 year
Incidence of cardiac death or readmission for heart failure during first 1 year follow-up.
Measured: 1 year
Cardiac death or readmission for heart failure in 2 years
Incidence of cardiac death or readmission for heart failure during first 2 years follow-up.
Measured: 2 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2023
- Study start1 Jun 2017
- Primary completion31 May 2022
- Study completion31 May 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Acute Myocardial Infarction (AMI)Studies of the same condition, open and under way.
- More trials run by Second Affiliated Hospital, Zhejiang University, School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 5,000 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Shengjing Hospital, RenJi Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05696379
- Sponsor's protocol ID
- 2022-0878
- Status last verified
- Dec 2022
- First submitted
- 13 Dec 2022
- Last updated
- 25 Jan 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Chen Z, Zhang Y, Fang J, Zheng Y, Chen D, Yidilisi A, Zhang X, Liu C, Huang J, Ji R, Chen J, Chen G, Lin P, Hu Y, Xiang J, Wang J, Jiang J. Thorough Physiological Assessment in Non-Culprit Vessels of Patients with Acute Myocardial Infarction: Is It a Required Action? Cardiovasc Drugs Ther. 2026 Jun;40(3):987-999. doi: 10.1007/s10557-025-07768-0. Epub 2025 Sep 6.
PubMed 40913743Chen D, Zhang Y, Yidilisi A, Hu D, Zheng Y, Fang J, Gong Q, Huang J, Dong Q, Pu J, Niu T, Xiang J, Wang J, Jiang J. Combined risk estimates of diabetes and coronary angiography-derived index of microcirculatory resistance in patients with non-ST elevation myocardial infarction. Cardiovasc Diabetol. 2024 Aug 16;23(1):300. doi: 10.1186/s12933-024-02400-1.
PubMed 39152477Zhang Y, Pu J, Niu T, Fang J, Chen D, Yidilisi A, Zheng Y, Lu J, Hu Y, Koo BK, Xiang J, Wang J, Jiang J. Prognostic Value of Coronary Angiography-Derived Index of Microcirculatory Resistance in Non-ST-Segment Elevation Myocardial Infarction Patients. JACC Cardiovasc Interv. 2024 Aug 26;17(16):1874-1886. doi: 10.1016/j.jcin.2024.04.048. Epub 2024 Aug 7.
PubMed 39115479
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Angiography Derived Index of Microcirculatory Resistance in Patients With Acute Myocardial Infarction
- ClinicalTrials.gov ID
- NCT05696379
- Acronym / sponsor ID
- 2022-0878
- Conditions
- Acute Myocardial Infarction (AMI)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 5,000 participants (actual)
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineUniversity, hospital or other
- Collaborators
- Shengjing Hospital, RenJi Hospital
- Study start
- 1 Jun 2017 (actual)
- Primary completion
- 31 May 2022 (actual)
- Study completion
- 31 May 2022 (actual)
- First posted
- 25 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Coronary microcirculatory dysfunction has been known to be prevalent even after successful revascularization of acute myocardial infarction (AMI) patients, and has been shown to be associated with poor prognosis. Angiography derived index of micro-circulatory resistance (Angio-IMR) is a novel pressure-wire free approach to assess coronary microvascular disease with great diagnostic performance. The current study will further investigate the prognostic value of Angio-IMR in patients with AMI in multicenter retrospective cohort.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| STEMI with high Angio-IMR | – | Other: Angiography derived index of micro-circulatory resistance (Angio-IMR)Patients with ST segment elevation myocardial infarction and high Angio-IMR |
| STEMI with low Angio-IMR | – | Other: Angiography derived index of micro-circulatory resistance (Angio-IMR)Patients with ST segment elevation myocardial infarction and low Angio-IMR |
| NSTEMI with high Angio-IMR | – | Other: Angiography derived index of micro-circulatory resistance (Angio-IMR)Patients with non-ST segment elevation myocardial infarction and high Angio-IMR |
| NSTEMI with low Angio-IMR | – | Other: Angiography derived index of micro-circulatory resistance (Angio-IMR)Patients with non-ST segment elevation myocardial infarction and low Angio-IMR |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients admitted with a diagnosis of acute myocardial infarction underwent successful percutaneous coronary intervention.
Key inclusion criteria (1 listed)
- Acute myocardial infarction patients who underwent successful percutaneous coronary intervention
Key exclusion criteria (2 listed)
- No appropriate coronary angiography images (inferior image quality, image loss, severe arteries overlap, or significant artifact)
- Previous coronary artery bypass graft
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Angiography derived index of micro-circulatory resistance (Angio-IMR)Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention. | Other | NSTEMI with high Angio-IMR, NSTEMI with low Angio-IMR, STEMI with high Angio-IMR, STEMI with low Angio-IMR |
Primary outcome
Cardiac death or readmission for heart failure in 1 month
Time frame: 1 month
Incidence of cardiac death or readmission for heart failure during first 1 month follow-up.
Cardiac death or readmission for heart failure in 6 months
Time frame: 6 month
Incidence of cardiac death or readmission for heart failure during first 6 months follow-up.
Cardiac death or readmission for heart failure in 1 year
Time frame: 1 year
Incidence of cardiac death or readmission for heart failure during first 1 year follow-up.
Cardiac death or readmission for heart failure in 2 years
Time frame: 2 year
Incidence of cardiac death or readmission for heart failure during first 2 years follow-up.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2023.
- Derived from this study: PubMed 40913743Chen Z, Zhang Y, Fang J, Zheng Y, Chen D, Yidilisi A, Zhang X, Liu C, Huang J, Ji R, Chen J, Chen G, Lin P, Hu Y, Xiang J, Wang J, Jiang J. Thorough Physiological Assessment in Non-Culprit Vessels of Patients with Acute Myocardial Infarction: Is It a Required Action? Cardiovasc Drugs Ther. 2026 Jun;40(3):987-999. doi: 10.1007/s10557-025-07768-0. Epub 2025 Sep 6.
- Derived from this study: PubMed 39152477Chen D, Zhang Y, Yidilisi A, Hu D, Zheng Y, Fang J, Gong Q, Huang J, Dong Q, Pu J, Niu T, Xiang J, Wang J, Jiang J. Combined risk estimates of diabetes and coronary angiography-derived index of microcirculatory resistance in patients with non-ST elevation myocardial infarction. Cardiovasc Diabetol. 2024 Aug 16;23(1):300. doi: 10.1186/s12933-024-02400-1.
- Derived from this study: PubMed 39115479Zhang Y, Pu J, Niu T, Fang J, Chen D, Yidilisi A, Zheng Y, Lu J, Hu Y, Koo BK, Xiang J, Wang J, Jiang J. Prognostic Value of Coronary Angiography-Derived Index of Microcirculatory Resistance in Non-ST-Segment Elevation Myocardial Infarction Patients. JACC Cardiovasc Interv. 2024 Aug 26;17(16):1874-1886. doi: 10.1016/j.jcin.2024.04.048. Epub 2024 Aug 7.
- Individual participant dataSharing planned: No
Related trials for Acute Myocardial Infarction (AMI)
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myocardial Infarction (AMI), run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cardiac death or readmission for heart failure in 1 month (time frame: 1 month). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05696379, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2023; AzTrials last refreshed its copy on 8 Nov 2026.